Shares of Orexigen Therapeutics Inc. (NASDAQ:OREX) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $3.18 and last traded at $3.19, with a volume of 105,997 shares trading hands. The stock had previously closed at $3.38.

Separately, Zacks Investment Research raised shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 7th. One analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. Orexigen Therapeutics presently has an average rating of “Hold” and a consensus target price of $2.61.

The firm’s market cap is $47.89 million. The stock has a 50 day moving average price of $4.04 and a 200-day moving average price of $7.25.

Orexigen Therapeutics (NASDAQ:OREX) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. The company earned $5 million during the quarter, compared to analysts’ expectations of $7.78 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. Orexigen Therapeutics’s revenue for the quarter was up 16.3% compared to the same quarter last year. Equities research analysts predict that Orexigen Therapeutics Inc. will post ($5.61) earnings per share for the current year.

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.